Table II.
Calcusyn output of median-effect analysis of Sora and Art combination in liver cancer cell lines.
| Parameters | CI value | DRI value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cell line | Drugs | Dm (µM) | m | r | IC50 | IC75 | IC90 | IC50 | IC75 | IC90 |
| HepG2 | Sora | 5.48 | 0.76 | 0.98 | 14.69 | 10.01 | 6.81 | |||
| Art | 81.5 | 0.69 | 0.93 | 21.86 | 17.48 | 13.98 | ||||
| Sora + Art (1:10) | 0.37+3.73 | 0.6 | 0.97 | 0.11 | 0.16 | 0.22 | ||||
| Huh7 | Sora | 16.44 | 1.33 | 0.91 | 3.04 | 4.57 | 6.46 | |||
| Art | 631.93 | 1.62 | 0.87 | 2.34 | 2.96 | 3.61 | ||||
| Sora + Art (1:50) | 5.39+270.05 | 2.29 | 0.98 | 0.75 | 0.56 | 0.43 | ||||
Dose-effect relationships were calculated by median-effect analysis using Calcusyn. m=1, m>1 and m<1 signify hyperbolic, sigmoidal and flat sigmoidal shapes, respectively. r indicates conformity of results. CI<1, CI=1 or CI>1, indicate synergism, additive or antagonism, respectively. DRI was measured by comparing the doses when used as a single treatment or in combination. Sora, sorafenib; Art, artesunate; CI, combination index; DRI, dose reduction index; Dm, median-effect dose that inhibits cell growth by 50%; r, linear correlation coefficient; IC50, half-maximal inhibitory concentration; IC75, 75% inhibitory concentration; IC90, 90% inhibitory concentration; m, shape of curve.